Outlook Therapeutics (OTLK) Gross Profit (2025 - 2026)

Outlook Therapeutics (OTLK) posted quarterly Gross Profit of -$21888.0 for Q1 2026, up 98.23% quarter-over-quarter from -$1.2 million in Q4 2025.

Outlook Therapeutics (OTLK) Gross Profit (2025 - 2026) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Gross Profit for 2 consecutive years, with -$21888.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Gross Profit changed N/A year-over-year to -$21888.0; the TTM figure through Mar 2026 stood at -$1.2 million (changed N/A YoY), while the FY2025 annual figure was $57205.0, changed N/A from the prior year.
Gross Profit rose to -$21888.0 in Q1 2026 per OTLK's latest filing, from -$1.2 million in the prior quarter.
Across five years, Gross Profit topped out at $1.1 million in Q2 2025 and bottomed at -$1.2 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Outlook Therapeutics	88.50 Mn	77.26 Mn	-8,265.00

Download Data